Project Grant R43DA063261
Award Date
5/15/25
Completion Date
4/30/26
Dollars Obligated
$400K
Federal Agency
National Institute on Drug Abuse
Awardee
Iontx Inc. (K7ZHCPD2VKE7)
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
This $319,547 project grant awarded on September 15, 2023 by the National Institute on Drug Abuse (NIDA) under the Drug Abuse and Addiction Research Programs (CFDA 93.279) supports Afasci, Inc.'s research and development of a novel treatment for cocaine use disorder (CUD). The project will investigate the effects of Afasci's investigational new drug AFA-281, which inhibits both the T-type Cav3 ion channels and soluble epoxide hydrolase, on reducing cocaine-seeking behavior and hyperlocomotion in...
This STTR Phase I Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $405,230 to Rafias LLC to advance the development of an NR4A1-targeted therapy for cocaine use disorder. The funding supports key milestones, including lead identification of novel NR4A1 agonist compounds derived from cytosporone B and lead optimization through characterization of the most promising candidates. This research builds...
This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $275,253 to Epivario Inc. to develop a novel epigenetic regulator as a treatment for opioid use disorder (OUD). The award supports screening of next-generation compounds targeting the metabolic enzyme ACSS2, which has been shown to play a key role in the encoding of drug-related memories. This research aims to identify a potent ACSS2 inhibitor that...
This $1,585,991 Project Grant award, funded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports a study to evaluate the effects of transcranial direct current stimulation (tDCS) combined with cognitive training on reducing craving and relapse in individuals with cocaine use disorder (CUD). The project aims to determine if synergistically enhancing dorsolateral prefrontal cortex (DLPFC) function through tDCS and cognitive...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $395,566 to support the development of a novel FDA-regulated pharmacotherapy for smoking cessation and nicotine de-addiction. The goal is to create a highly structured, multimodal nicotine cessation program with dramatically higher efficacy than current standard-of-care treatments. This Phase I proposal aims to fund the initial...
The National Institute on Drug Abuse (NIDA) awarded a $19,302,777 Cooperative Agreement (CFDA 93.279 - Drug Use and Addiction Research Programs) to Nirsum Laboratories, Inc. to accelerate the development of NRS-033, a novel medication for the treatment of opioid use disorder (OUD). The project aims to advance late-stage chemistry, manufacturing, and controls (CMC), conduct registration-enabling non-clinical studies, establish quality systems, and engage with the FDA to expedite NRS-033 into...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund a research program that investigates the interplay between drug-induced long-term synaptic proteomic adaptations and the underlying transcriptional responses within the brain's reward regions, specifically the nucleus accumbens. The total funding for this 5-year award is $180,606. The research aims to elucidate the cocaine-induced cell-type and...
This $1,447,919 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research into understanding and treating substance use disorders, particularly cocaine addiction. The key products or services to be delivered through this funding include: Testing the hypothesis that addiction involves a "hijacking" of physiological need-state substrates, in addition to reward substrates. The research will...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $398,137 to Boston Interactome LLC to develop high-precision epigenetic therapeutics for opioid use disorder (OUD). The project aims to identify small-molecule compounds that can selectively modulate the G9A protein complex, which regulates the expression of DFosB in the brain during chronic opioid exposure. The work will involve a...
The National Institute on Drug Abuse (NIDA) has awarded a $586,936 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Vitan-Biotech LLC, a minority-owned biotechnology company in Aurora, Colorado. The funding will support the development of a low-cost, disposable urine test strip that can rapidly and quantitatively measure the concentrations of substance use disorder (SUD) medication drugs, such as buprenorphine, methadone, and naltrexone, as well as their...